Effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole

Safra, Tamar; Bernstein Molho, R.; Stephansky, I.; Yaal‐Hahoshen, Neora; Inbar, Moshe; Ackerstein, Aliza; Geffen, D.

doi:10.1200/jco.2009.27.15_suppl.599

Public

Effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole

Shared by NobleBlocks on May 20, 2009 • 12:00 AM UTC

Authors:

Tamar Safra

R. Bernstein Molho

I. Stephansky

Abstract

599 Background: Adjuvant treatment with aromatase inhibitors (AIs) in postmenopausal women (PMW) with early breast cancer (EBC) can be associated with decreased bone mineral density (BMD) and increased risk of osteoporosis and fractures. Tamoxifen (TAM) has bone protective effect. BIG 1–98 recent, 7...

Subject

Medicine

Letrozole

Zoledronic acid

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!